The new indications of the antidepressant drug Brintellix of Lingbei pharmaceutical have been supported by CHMP. This drug will soon become the first antidepressant approved in the EU to improve the cognitive function of patients with depression. The new indications are based on the results of the connecting test. The results show that when compared with placebo, vortioxetine and Lilly's antidepressant competitive product duloxetine can better improve various cognitive indexes of patients.
People with severe depression usually report a series of cognitive symptoms, including obvious difficulties in thinking, attention, and memory of new information, which can damage patients' self-confidence and lead to social disharmony. Although cognitive problems have been well recognized in other mental diseases such as schizophrenia, there are few studies on their impact on depression.
„Wir freuen uns, dass Vortioxetin vom CHMP positive Kommentare erhalten hat, insbesondere zum Status der kognitiven Beeinträchtigung bei der Auswirkung auf das Behandlungsergebnis der meisten Patienten“, sagte Pedersen, Direktor von Lingbei für Forschung und Entwicklung. Die ermutigenden Daten, die wir bei der Behandlung kognitiver Störungen gesehen haben, lassen uns glauben, dass Vortioxetin das Potenzial hat, vielen Patienten bei der Behandlung ihrer Depression zu helfen.
Votexetine has been listed in the United States for only more than a year, and it is gradually lifted in the whole EU. Last September, it was listed in Denmark, Lingbei's hometown. It is reported that this drug is the fastest-growing new antidepressant in the United States in the past three years. This drug is jointly listed by Lingbei and Takeda in the United States.
Das sind gute Nachrichten für Lingbei, denn es braucht neue Medikamente, um die Folgen des Patentablaufs seines alten Antidepressivums Idprem auszugleichen. Yidepulum war ein Blockbuster-Medikament mit einem Jahresumsatz von mehreren Milliarden Dollar, das durch die Konkurrenz von Generika beeinträchtigt wurde.
Votexetine sold 188 million kroner (27 million) in six EU markets last year, compared with 83 million kroner in the fourth quarter alone, so it still has some ways to catch up with Idem. Although Idprem no longer has a market franchise, it still sold 4.6 billion kroner. The Danish company also has long-acting schizophrenic drug aripiprazole and an alcohol addiction treatment drug nalmefene, which can help vortioxetine increase the company's revenue again.